Stock 603538 NINGBO MENOVO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ningbo Menovo Pharmaceutical Co., Ltd.

Equities

603538

CNE100002Y25

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
11.97 CNY +1.96% Intraday chart for Ningbo Menovo Pharmaceutical Co., Ltd. +1.87% -37.40%
May. 24 China Approves Menovo Pharma's Type 2 Diabetes Drug MT
Apr. 29 Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
China Approves Menovo Pharma's Type 2 Diabetes Drug
MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Menovo Pharmaceutical Unit Gets Approval to Register Vildagliptin Tablets
MT
Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on July 20, 2023
CI
Menovo Pharma's Unit Gets Nod to Market Clopidogrel Hydrogen Sulfate Tablets
MT
Menovo Pharma Gets Nod to Market Raw Drug Ingredient for Hypertension Into EU Market; Shares Up 3%
MT
Ningbo Menovo Pharmaceutical Co., Ltd.(XSSC:603538) dropped from S&P Global BMI Index
CI
Ningbo Menovo Pharma Registers Seizure Drug in China
MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Menovo Pharmaceutical Unit's Rosuvastatin Calcium Passes Drug Regulator's Technical Review
MT
Ningbo Menovo Pharmaceutical Co., Ltd.(XSSC:603538) added to S&P Global BMI Index
CI
Ningbo Menovo Pharma Registers Blood Pressure Drug
MT
Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 652 million in funding from Ningbo Menovo Holding Group Co., Ltd. and other investors
CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive CNY 651.999948 million in funding from Ningbo Menovo Holding Group Co., Ltd. and other investors.
CI
Ningbo Menovo Pharmaceutical Co., Ltd. announced that it expects to receive funding from Ningbo Menovo Holding Group Co., Ltd.
CI
Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on August 15, 2022
CI
Menovo Pharmaceutical's Unit Gets Nod to Own Olmesartan Medoxomil Tablets
MT
Menovo Pharma Gets European Certification for Diet Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603538 Stock
  4. News Ningbo Menovo Pharmaceutical Co., Ltd.